There are currently 138 clinical trials in Newark, New Jersey looking for participants to engage in research studies. Trials are conducted at various facilities, including Newark Beth Israel Medical Center, Rutgers New Jersey Medical School, Saint Michael's Medical Center and University Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption
NCT04340596
Recruiting
The purpose of this study is to evaluate the safety, tolerability, and efficacy of N-803, an IL-15 superagonist, with or without combination broadly neutralizing antibodies (bNAbs), to induce HIV-1 control during analytic treatment interruption (ATI).
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/12/2024
Locations: New Jersey Medical School Clinical Research Center CRS [Site ID: 31786], Newark, New Jersey
Conditions: HIV Infection
Register for Updates
AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension
NCT04499248
Recruiting
This is a multicenter, open-label, dose escalation (Cohort 1) to masked, randomized, parallel-groups (Cohort 2) and (Cohort 3) study to evaluate the safety and efficacy of AGN-193408 SR in participants with open-angle glaucoma or ocular hypertension
Gender:
All
Ages:
18 years and above
Trial Updated:
04/11/2024
Locations: Rutgers New Jersey Medical School Campus, Doctors Office Center /ID# 234365, Newark, New Jersey
Conditions: Open-angle Glaucoma, Ocular Hypertension
Register for Updates
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
NCT03007147
Recruiting
This randomized phase III trial studies how well imatinib mesylate works in combination with two different chemotherapy regimens in treating patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (ALL). Imatinib mesylate has been shown to improve outcomes in children and adolescents with Philadelphia chromosome positive (Ph+) ALL when given with strong chemotherapy, but the combination has many side effects. This trial is testing whether a different chemother... Read More
Gender:
All
Ages:
Between 1 year and 21 years
Trial Updated:
04/10/2024
Locations: Newark Beth Israel Medical Center, Newark, New Jersey
Conditions: Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia, T Acute Lymphoblastic Leukemia
Register for Updates
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
NCT00736749
Recruiting
This clinical trial keeps track of and collects follow-up information from patients who are currently enrolled on or have participated in a Children's Oncology Group study. Developing a way to keep track of patients who have participated in Children's Oncology Group studies may allow doctors learn more about the long-term effects of cancer treatment and help them reduce problems related to treatment and improve patient quality of life.
Gender:
All
Ages:
All
Trial Updated:
04/10/2024
Locations: Newark Beth Israel Medical Center, Newark, New Jersey
Conditions: Hematopoietic Cell Transplantation Recipient, Leukemia, Solid Tumor
Register for Updates
Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy
NCT03970343
Recruiting
The OPTIMIZER Smart Post-Approval Study is a prospective, multi-center, non-randomized, single arm open label study of 620 subjects receiving an OPTIMIZER implant as standard of care. Patients to be included will have NYHA functional class III symptoms and a left ventricular ejection fraction of 25-45%
Gender:
All
Ages:
18 years and above
Trial Updated:
04/09/2024
Locations: Rutgers Medical School, Newark, New Jersey
Conditions: Heart Failure
Register for Updates
ATATcH Alternating Treatment Plans for Advanced Cancer
NCT05358548
Recruiting
The purpose of the research is to evaluate a new schedule of alternating cycles of induction chemoimmunotherapy (chemotherapy plus pembrolizumab) and immunotherapy (pembrolizumab) alone for the initial treatment of patients with advanced lung or head and neck cancers.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/09/2024
Locations: RWJBarnabas Health - Newark Beth Israel Medical Center, Newark, New Jersey
Conditions: Head and Neck Cancer, Lung Cancer
Register for Updates
AMPLATZER PFO Occluder Post Approval Study
NCT03309332
Recruiting
The purpose of this single arm, multi-center study is to confirm the safety and effectiveness of the AMPLATZER™ PFO Occluder in the post Approval Setting.
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
04/08/2024
Locations: Newark Beth Israel Medical Center, Newark, New Jersey
Conditions: Stroke, Patent Foramen Ovale
Register for Updates
Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors
NCT00082745
Recruiting
This clinical trial studies cancer survivors to identify those who are at increased risk of developing late-occurring complications after undergoing treatment for childhood cancer. A patient's genes may affect the risk of developing complications, such as congestive heart failure, avascular necrosis, stroke, and second cancer, years after undergoing cancer treatment. Genetic studies may help doctors identify survivors of childhood cancer who are more likely to develop late complications.
Gender:
All
Ages:
99 years and below
Trial Updated:
04/05/2024
Locations: Newark Beth Israel Medical Center, Newark, New Jersey
Conditions: Childhood Malignant Neoplasm
Register for Updates
Neuropsychological and Behavioral Testing in Younger Patients With Cancer
NCT00772200
Recruiting
This research trial studies neuropsychological (learning, remembering or thinking) and behavioral outcomes in children and adolescents with cancer by collecting information over time from a series of tests.
Gender:
All
Ages:
1 month and above
Trial Updated:
04/05/2024
Locations: Newark Beth Israel Medical Center, Newark, New Jersey
Conditions: Childhood Malignant Neoplasm
Register for Updates
FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study
NCT05639543
Recruiting
The purpose of this trial is to assess dose related safety, efficacy, and pharmacokinetics (PK) of INT-787 in participants with severe alcohol-associated hepatitis (sAH).
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/04/2024
Locations: Rutgers-New Jersey Medical School, Newark, New Jersey
Conditions: Alcohol Associated Hepatitis
Register for Updates
Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted
NCT05559164
Recruiting
This study proposes that the addition of statins reduces the treatment delays or early discontinuations secondary to cardiotoxicity in patients with Stage I-III HER2 positive breast being treated with anti-HER2 therapy.
Gender:
Female
Ages:
18 years and above
Trial Updated:
04/01/2024
Locations: RWJBarnabas Health - Newark Beth Israel Medical Center, Newark, New Jersey
Conditions: Cardiac Toxicity, Early-stage Breast Cancer
Register for Updates
To Compare the Efficacy and Safety of the HAV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis
NCT05908084
Recruiting
The goal of this clinical trial is to compare the number of catheter-free days (CFD) and the rate and severity of any dialysis access-related infections between the HAV and AVF groups over 12 months in patients with end-stage renal disease (ESRD) needing hemodialysis (HD). Participants will be stratified by location of the vascular access (forearm versus upper arm) and by type of AVF creation procedure planned by the surgeon at randomization (1-stage AVF versus 2-stage AVF). The comparator is a... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
04/01/2024
Locations: Rutgers University_Medical, Newark, New Jersey
Conditions: End Stage Renal Disease (ESRD)
Register for Updates